These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37950531)

  • 41. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
    Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system.
    Ou Z; Han Y; Zhuang W; Xiao Y; Cai S; Zhang X
    Int J Clin Pharmacol Ther; 2024 Nov; 62(11):497-506. PubMed ID: 39099387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
    Liu L; Chen J; Wang L; Chen C; Chen L
    Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
    Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
    Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.
    Kim OM; Givens TK; Tang EG; Schimmer JJ; Ramsey T; Boyd K; Delate T
    J Cardiovasc Pharmacol; 2023 May; 81(5):339-347. PubMed ID: 36795508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
    Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
    Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
    Zhao D; Long X; Zhou J; Wang J
    Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS).
    Xiong X; Zhang X; Li X; Huang T
    Expert Opin Drug Saf; 2024 Nov; 23(11):1447-1452. PubMed ID: 38404234
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization.
    Huynh-Le MP; Shults RC; Connor MJ; Hattangadi-Gluth JA
    Clin Genitourin Cancer; 2020 Jun; 18(3):192-200.e2. PubMed ID: 31902714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease.
    Blumenthal DM; Maddox TM; Aragam K; Sacks CA; Virani SS; Wasfy JH
    Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007237. PubMed ID: 34404223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system.
    Zhao Y; Jiang H; Xue L; Zhou M; Zhao X; Liu F; Jiang S; Huang J; Meng L
    Int J Clin Pharm; 2024 Apr; 46(2):480-487. PubMed ID: 38245663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
    Shu Y; Wang L; Ding Y; Zhang Q
    Drug Saf; 2023 Sep; 46(9):881-895. PubMed ID: 37418089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
    Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
    J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system.
    Zhao D; Long X; Wang J
    BMC Pharmacol Toxicol; 2024 Feb; 25(1):20. PubMed ID: 38395895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluoroquinolones-related psychiatric adverse events: a real‑world retrospective and pharmacovigilance database analysis.
    Li J; Yin X; Zhao Y; Yang X; Wang J; Yuan T; Zheng J; Tang Q; Wei W
    Expert Opin Drug Saf; 2024 Aug; ():1-14. PubMed ID: 39082071
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias' treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis.
    Pamporis K; Karakasis P; Simantiris S; Sagris M; Bougioukas KI; Fragakis N; Tousoulis D
    Clin Investig Arterioscler; 2024; 36(2):86-100. PubMed ID: 38040529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study.
    Liu H
    Front Pharmacol; 2024; 15():1353848. PubMed ID: 39148544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.
    Wang J; Zhang A; Ye M; Zhang C
    Front Pharmacol; 2024; 15():1376535. PubMed ID: 38562462
    [No Abstract]   [Full Text] [Related]  

  • 60. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
    Sato K; Mano T; Iwata A; Toda T
    J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.